Form 8-K - Current report:
SEC Accession No. 0001213900-25-063475
Filing Date
2025-07-14
Accepted
2025-07-14 08:00:43
Documents
15
Period of Report
2025-07-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248789-8k_cero.htm   iXBRL 8-K 36692
2 COMMON STOCK PURCHASE AGREEMENT, BY AND BETWEEN CERO THERAPEUTICS HOLDINGS, INC. ea024878901ex10-1_cero.htm EX-10.1 469181
3 REGISTRATION RIGHTS AGREEMENT, BY AND BETWEEN CERO THERAPEUTICS HOLDINGS, INC., ea024878901ex10-2_cero.htm EX-10.2 144175
  Complete submission text file 0001213900-25-063475.txt   988943

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cero-20250711.xsd EX-101.SCH 3829
5 XBRL DEFINITION FILE cero-20250711_def.xml EX-101.DEF 26720
6 XBRL LABEL FILE cero-20250711_lab.xml EX-101.LAB 36917
7 XBRL PRESENTATION FILE cero-20250711_pre.xml EX-101.PRE 25344
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0248789-8k_cero_htm.xml XML 6043
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 251120170
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)